• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Citeline Launches AI-Powered Tools for Clinical Trials

by Jasmine Pennic 08/13/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Citeline, a provider of intelligence solutions for the life sciences industry, today announced the launch of Protocol SmartDesign and Investigator SmartSelect, two new AI-powered tools designed to streamline and optimize clinical trial development. 

– These innovative solutions are part of the Citeline SmartSolutions suite, which leverages the company’s extensive data assets to deliver actionable insights for life sciences organizations.

How Protocol SmartDesign Works

Protocol SmartDesign utilizes AI and machine learning to analyze vast amounts of data, including clinical trial data, real-world evidence, and patient demographics. This enables researchers to make informed decisions about protocol design, endpoint selection, and patient inclusion/exclusion criteria. By leveraging historical performance data, the tool can also help predict enrollment rates and trial duration.

Investigator SmartSelect streamlines the process of identifying and selecting qualified investigators for clinical trials. By combining AI with Citeline’s extensive investigator database, the tool can quickly generate a pool of potential sites and investigators based on specific protocol criteria. This significantly reduces the time and effort required for site selection, allowing researchers to focus on other critical aspects of trial design.

Both Protocol SmartDesign and Investigator SmartSelect are designed to reduce the likelihood of costly protocol amendments, which can significantly impact trial timelines and budgets. According to the Tufts Center for the Study of Drug Development, protocol amendments can add substantial costs to clinical trials. By optimizing protocol design and investigator selection, Citeline’s solutions help to mitigate this risk. “These solutions not only produce significant savings for medical, clinical operations and feasibility teams in terms of both time and cost, they ease the burden on study teams and site staff,” said Maureen Ladouceur, RN, president of Norstella, Citeline’s parent company. “As a clinician, this personally means a lot to me.”  

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Clinical Trials

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Particle Health Addresses Integration to Epic Data Despite Dispute

US Court Allows Particle’s Antitrust Claims Against Epic to Proceed

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

Sage Growth Partners Report: Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |